Drug intelligence / Profile preview

proton pump inhibitor + amoxicillin + metronidazole

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

A combination therapy consisting of a **proton pump inhibitor (PPI)**, **amoxicillin**, and **metronidazole** is used as a triple therapy primarily for the eradication of *Helicobacter pylori* infection in the stomach. The PPI reduces gastric acid secretion, thereby enhancing the effectiveness of the antibiotics and providing ulcer healing. **Amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while **metronidazole** is a nitroimidazole antibiotic effective against anaerobic bacteria, including *H. pylori*. This regimen is often used as an alternative to clarithromycin-containing regimens, especially in areas with high clarithromycin resistance. Efficacy depends on duration and dosing, with 14-day regimens and higher metronidazole doses associated with higher cure rates. The combination is globally recommended in guidelines as a first-line or alternative therapy for *H. pylori* eradication[2][5][6].

02

Targets

NeuraminidasePBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on proton pump inhibitor + amoxicillin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on proton pump inhibitor + amoxicillin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call